Irina Talia Guzmán Chávez

Irina Talia Guzmán Chávez

Auto-generated profile, based on publicly available information

Irina Talia Guzmán Chávez

Ministerio de Salud Púbica, Ecuador

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2024 in Ibero-American Journal of Health Science Research
Verified
Journal Article
Open access
PDF file
AAAna Gabriela Aillón Albán
Ana Gabriela Aillón Albán
FNFernanda De Las Mercedes López Naveda
Fernanda De Las Mercedes López Naveda
ICIrina Talia Guzmán Chávez
Irina Talia Guzmán Chávez
AAAndrea Carolina Arregui Ayala
Andrea Carolina Arregui Ayala
CBClara Noemi Sivisaca Bonifaz
Clara Noemi Sivisaca Bonifaz
Combination therapy with immune checkpoint inhibitors, specifically CTLA-4 and PD-1 blockade, has shown promise in treating advanced melanoma. However, this approach often results in increased toxicity, necessitating a careful evaluation of both efficacy and safety. This review explores clinical outcomes, survival rates, and adverse events associated with these therapies. A systematic review of PubMed, Scopus, and clinical trial databases was conducted for studies published from 2014 to 2024. Studies assessing the combined use of CTLA-4 and PD-1 inhibitors in melanoma patients were included, focusing on overall survival (OS), progression-free survival (PFS), and treatment-related adverse events (AEs). The combination of CTLA-4 and PD-1 inhibitors significantly improved clinical outcomes in advanced melanoma. In trials like CheckMate 067, the five-year overall survival rate reached 52%, with a notable improvement in progression-free survival. However, these benefits came with substantial toxicity, as approximately 55% of patients experienced grade 3 or 4 treatment-related adverse events, including colitis, hepatitis, and pneumonitis. Despite these challenges, combination therapy led to durable responses in a subset of patients, underscoring its efficacy. The review emphasizes the need for balancing efficacy with toxicity management in clinical practice. While CTLA-4 and PD-1 inhibitor combinations improve survival in advanced melanoma, increased toxicity presents challenges. Further research is needed to optimize treatment strategies and enhance patient selection to balance efficacy and safety.

1 July 2024 in Ibero-American Journal of Health Science Research
Verified
Journal Article
Open access
FNFernanda De Las Mercedes López Naveda
Fernanda De Las Mercedes López Naveda
AAAkemi Rocío Plaza Alcívar
Akemi Rocío Plaza Alcívar
ICIrina Talia Guzmán Chávez
Irina Talia Guzmán Chávez
ACAna Karina Guamán Cevallos
Ana Karina Guamán Cevallos
AVAnthony Jesús Pastrana Villares
Anthony Jesús Pastrana Villares
ABAna Gabriela Castro Bojorque
Ana Gabriela Castro Bojorque
Background: Atopic dermatitis (AD)_ chronic inflammatory skin disorder, has affected the global population. Specifically, it is seen as more common in children about 10-20% prevalence in children’s and 2% among adults. Traditional treatments are insufficient for moderate to severe cases and necessitate new therapeutic options. Janus kinase (JAK) inhibitors is promising class of drugs due to their ability to modulate key inflammatory pathways involved in AD. Methodology: Systematic review was conducted using Cochrane Library database, PubMed, and Embase. Keywords and MeSH terms identified studies focusing on adult patients with moderate to severe AD. Inclusion criteria encompassed studies evaluating efficacy and safety of JAK inhibitors. Data extraction was performed using standardized forms, Cochrane Risk of Bias Tool conducted. Most of the articles are selected which are published in 2024 to keep our research up-to-date. Results: We have analyzed data from several studies evaluating the efficacy and safety of JAK inhibitors, most commonly abrocitinib, upadacitinib, and baricitinib. They have shown efficacy in reducing eczema symptoms with EASI-75 response rates of up to 80% for upadacitinib and 71% for abrocitinib. Higher doses of JAK inhibitors raised safety concerns like heart diseases, infections, and acne, but the standard recommended dose stood beneficial in reducing eczema. Conclusion: JAK inhibitors are advancements in the treatment of moderate to severe atopic dermatitis. They offer substantial symptom relief and improved quality of life.